Treatment of Bipolar Depression

First-Line Pharmacological Options

The American Psychiatric Association recommends olanzapine-fluoxetine combination as first-line therapy for bipolar depression, due to its strong evidence for acute efficacy 1, 2
Quetiapine monotherapy is an equally strong first-line option, particularly when metabolic concerns with olanzapine are prohibitive, as recommended by the American Psychiatric Association 1, 2
Lithium or lamotrigine should be considered as foundational mood stabilizers, though their acute antidepressant efficacy is more modest, according to the American Psychiatric Association 1, 2

For patients not currently on a mood stabilizer, the American Psychiatric Association recommends starting with olanzapine-fluoxetine combination, with quetiapine monotherapy as an alternative if metabolic concerns exist 1
For patients already on an adequate mood stabilizer, the American Psychiatric Association recommends adding lamotrigine to existing lithium therapy, or adding quetiapine to existing mood stabilizer for more rapid symptom control 1, 2

The American Psychiatric Association advises against using antidepressant monotherapy due to high risk of mood destabilization, manic switching, and rapid cycling 1, 2
SSRIs, particularly fluoxetine, or bupropion are preferred antidepressants when adding to mood stabilizers, as they carry lower risk of inducing mania, according to the American Psychiatric Association 3
Maintenance therapy must continue for at least 12-24 months after acute episode resolution, with many patients requiring lifelong treatment, as recommended by the American Psychiatric Association 1, 3

The American Psychiatric Association recommends baseline metabolic assessment before starting atypical antipsychotics, including BMI, waist circumference, blood pressure, fasting glucose, and lipid panel 1
Follow-up monitoring schedule should include BMI monthly for 3 months then quarterly, and blood pressure, glucose, and lipids at 3 months then yearly, according to the American Psychiatric Association 1
For lithium, the American Psychiatric Association recommends monitoring levels, renal function, and thyroid function every 3-6 months 1, 3

The American Academy of Child and Adolescent Psychiatry recommends psychoeducation as essential, providing information to both patient and family regarding symptoms, course, treatment options, medication adherence, and relapse prevention 4, 1, 3, 2
Cognitive-behavioral therapy and family-focused therapy have demonstrated efficacy as adjuncts to pharmacotherapy, improving medication compliance and reducing relapse rates, according to the American Academy of Child and Adolescent Psychiatry 4, 3, 2